A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
To test the efficacy of CP-751,871 combined with exemestane in the treatment of postmenopausal patients with hormone positive advanced breast cancer
Inclusion Criteria:
Exclusion Criteria:
Washington D.C., District of Columbia 20010-3017, United States
Minneapolis, Minnesota 55454, United States
Burlington, North Carolina 27215-8700, United States
Durham, North Carolina 27710, United States
Durham, North Carolina 27710, United States
Porto Alegre, Rio Grande do Sul 90430-090, Brazil
São Paulo, São Paulo 05403-900, Brazil
Milan, 20141, Italy
Padova, 35128, Italy